Dyslipidemia

Adding evolocumab to existing lipid-lowering therapies significantly reduced first MACE risk, highlighting its efficacy in reducing cardiovascular mortality.

Alterations in appetite and weight may have influenced abdominal adiposity, as well as inflammatory and cardiometabolic markers.

This conference preview with Viet Le, DMSc, PA-C, for the 2025 AHA Scientific Sessions highlights the top 5 trials to watch.

A recent study highlights correlations between later healing, triglyceride levels, and total cholesterol in patients receiving MH.

A pooled cohort analysis of the phase 3 BROOKLYN and BROADWAY trials spotlighted obicetrapib’s impact on patients at risk of cardiovascular mortality.

Read about groundbreaking FDA decisions, exciting new heart failure research, and more.

The extended indication includes children 1 to < 5 years of age with homozygous familial hypercholesterolemia.

Despite the global prevalence of hypercholesterolemia, only 11% of children receive lipid screening, leaving many cases undiagnosed.

New research supports fimasartan, atorvastatin, and ezetimibe combination to blood pressure and cholesterol levels.

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

Patients with hypercholesterolemia on individualized maximally tolerated dose of statins achieved guideline-recommended LDL-C levels on inclisiran.

Merck’s investigational oral PCSK9 inhibitor reduced LDL-C, non-HDL-C, ApoB, and LP(a) significantly compared to placebo after 24 weeks.

Ionis Therapeutics, Inc. also announced plans to submit an sNDA for olezarsen based on these trial results by the end of 2025.

Olezarsen shows promise in significantly lowering triglyceride levels in patients with hypertriglyceridemia.

According to investigators, individuals with 3 or more risk factors for metabolic syndrome have a 40% greater risk of developing Parkinson’s.

A series of phase 2/3 trials collectively indicate the overall lipid-lowering effects of obicetrapib in a 5 mg dose, a 10 mg dose, and 10 mg with ezetimibe.

Parent company Response Pharmaceuticals has announced RDX-002’s achievement of its primary endpoint, with more data to come from an ongoing extension.

July delivered 9 impactful advancements across the gamut of disciplines in cardiology.

Discover the evolving landscape of hypertriglyceridemia treatment, focusing on innovative therapies and improved diagnostic strategies for FCS and MCS.

Inclisiran can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in hypercholesterolemia.

Actual LLT use was significantly lower than the proportion of guideline-eligible patients for statins, ezetimibe, and PCSK9i.

Our recap of Q2 2025 in cardiology spotlights 3 FDA headlines, trial news, and new episodes of Don't Miss a Beat.

Phase 3 trials show enlicitide decanoate significantly lowers LDL cholesterol, offering a promising oral treatment for hyperlipidemia and cardiovascular risk.

Discover key advancements and setbacks in cardiovascular medicine from May 2025, shaping the future of cardiometabolic care and treatment options.

The FDA approves hydrocortisone oral solution for pediatric adrenal insufficiency, enhancing dosing accuracy and ease for young patients and caregivers.